{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:04Z","timestamp":1794047404228,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Aggressive B-cell malignancies, such as mantle cell lymphoma (MCL), are microenvironment-dependent tumors and a better understanding of the dialogs occurring in lymphoma-protective ecosystems will provide new perspectives to increase treatment efficiency. To identify novel molecular regulations, we performed a transcriptomic analysis based on the comparison of circulating MCL cells (n=77) versus MCL lymph nodes (n=107) together with RNA sequencing of malignant (n=8) versus normal B-cell (n=6) samples. This integrated analysis led to the discovery of microenvironment-dependent and tumor-specific secretion of interleukin-32 beta (IL32\u03b2), whose expression was confirmed in situ within MCL lymph nodes by multiplex immunohistochemistry. Using ex vivo models of primary MCL cells (n=23), we demonstrated that, through the secretion of IL32\u03b2, the tumor was able to polarize monocytes into specific MCL-associated macrophages, which in turn favor tumor survival. We highlighted that while IL32\u03b2-stimulated macrophages secreted several protumoral factors, they supported tumor survival through a soluble dialog, mostly driven by BAFF. Finally, we demonstrated the efficacy of selective NIK\/alternative-NFkB inhibition to counteract microenvironment-dependent induction of IL32\u03b2 and BAFF-dependent survival of MCL cells. These data uncovered the IL32\u03b2\/BAFF axis as a previously undescribed pathway involved in lymphoma-associated macrophage polarization and tumor survival, which could be counteracted through selective NIK inhibition.<\/jats:p>","DOI":"10.3324\/haematol.2021.279800","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T03:09:45Z","timestamp":1646881785000},"page":"2905-2917","source":"Crossref","is-referenced-by-count":19,"title":["The IL32\/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition"],"prefix":"10.3324","volume":"107","author":[{"given":"Salom\u00e9","family":"Decombis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Papin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Sortais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Bris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiphanie","family":"Riveron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Blandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Rouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Moreau-Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"42240","doi-asserted-by":"crossref","unstructured":"Maman S, Witz IP. A history of exploring cancer in context. Nat Rev Cancer. 2018; 18(6):359-376.","DOI":"10.1038\/s41568-018-0006-7"},{"key":"42241","doi-asserted-by":"crossref","unstructured":"Jin M-Z, Jin W-L. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):1-16.","DOI":"10.1038\/s41392-020-00280-x"},{"key":"42242","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Morschhauser F, Chiron D. Ibrutinib, obinutuzumab and venetoclax in relapsed and untreated patients with mantle-cell lymphoma, a phase I\/II trial. Blood. 2020; 137(7):877.","DOI":"10.1182\/blood.2020008727"},{"key":"42243","doi-asserted-by":"crossref","unstructured":"Pytlik R, Polgarova K, Karolova J, Klener P. Current immunotherapy approaches in non-Hodgkin lymphomas. Vaccines. 2020; 8(4):708.","DOI":"10.3390\/vaccines8040708"},{"key":"42244","doi-asserted-by":"crossref","unstructured":"Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015; 125(1):48-55.","DOI":"10.1182\/blood-2014-05-521898"},{"key":"42245","doi-asserted-by":"crossref","unstructured":"Delfau-Larue M-H, Klapper W, Berger F. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015; 126(5):604-611.","DOI":"10.1182\/blood-2015-02-628792"},{"key":"42246","doi-asserted-by":"crossref","unstructured":"Eskelund CW, Dahl C, Hansen JW. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017; 130(17):1903-1910.","DOI":"10.1182\/blood-2017-04-779736"},{"key":"42247","doi-asserted-by":"crossref","unstructured":"Nadeu F, Martin-Garcia D, Clot G. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020; 136(12):1419-1432.","DOI":"10.1182\/blood.2020005289"},{"key":"42248","doi-asserted-by":"crossref","unstructured":"Agarwal R, Chan Y-C, Tam CS. Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019; 25(1):119-129.","DOI":"10.1038\/s41591-018-0243-z"},{"key":"42249","doi-asserted-by":"crossref","unstructured":"Chiron D, Di Liberto M, Martin P. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014; 4(9):1022-1035.","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"42250","doi-asserted-by":"crossref","unstructured":"Rahal R, Frick M, Romero R. Pharmacological and genomic profiling identifies NF-\u03baB\u2013targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014; 20(1):87-92.","DOI":"10.1038\/nm.3435"},{"key":"42251","doi-asserted-by":"crossref","unstructured":"Papin A, Tessoulin B, Bellanger C. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019; 33(10):2442-2453.","DOI":"10.1038\/s41375-019-0463-3"},{"key":"42252","doi-asserted-by":"crossref","unstructured":"Chiron D, Bellanger C, Papin A. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016; 128(24):2808-2818.","DOI":"10.1182\/blood-2016-06-720490"},{"key":"42253","doi-asserted-by":"crossref","unstructured":"Tessoulin B, Papin A, Gomez-Bougie P. BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker. Front Oncol. 2018; 8:645.","DOI":"10.3389\/fonc.2018.00645"},{"key":"42254","doi-asserted-by":"crossref","unstructured":"Saba NS, Liu D, Herman SE. Pathogenic role of B-cell receptor signaling and canonical NF-KB activation in mantle cell lymphoma. Blood. 2016; 128(1):82-92.","DOI":"10.1182\/blood-2015-11-681460"},{"key":"42255","doi-asserted-by":"crossref","unstructured":"Ferrer A, Salaverria I, Bosch F. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer. 2007; 109(12):2473-2480.","DOI":"10.1002\/cncr.22715"},{"key":"42256","doi-asserted-by":"crossref","unstructured":"Hanf M, Chiron D, de Visme S. The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. BMC Cancer. 2016; 16(1):802.","DOI":"10.1186\/s12885-016-2844-6"},{"key":"42257","doi-asserted-by":"crossref","unstructured":"Charpentier E, Cornec M, Dumont S. 3\u2019RNA sequencing for robust and low-cost gene expression profiling. 2021. Publisher Full Text|","DOI":"10.21203\/rs.3.pex-1336\/v1"},{"key":"42258","doi-asserted-by":"crossref","unstructured":"Rawal S, Chu F, Zhang M. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol. 2013; 190(12):6681-6693.","DOI":"10.4049\/jimmunol.1201363"},{"key":"42259","doi-asserted-by":"crossref","unstructured":"Burke JR, Pattoli MA, Gregor KR. BMS-345541 is a highly selective inhibitor of IKB kinase that binds at an allosteric site of the enzyme and blocks NF-KB-dependent transcription in mice. J Biol Chem. 2003; 278(3):1450-1456.","DOI":"10.1074\/jbc.M209677200"},{"key":"42260","doi-asserted-by":"crossref","unstructured":"Brightbill HD, Suto E, Blaquiere N. NF-KB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun. 2018; 9(1):1-14.","DOI":"10.1038\/s41467-017-02672-0"},{"key":"42261","doi-asserted-by":"crossref","unstructured":"Sloot YJ, Smit JW, Joosten LA, Netea-Maier RT. Insights into the role of IL-32 in cancer. Semin Immunol. 2018; 38:24-32.","DOI":"10.1016\/j.smim.2018.03.004"},{"key":"42262","doi-asserted-by":"crossref","unstructured":"Aass KR, Kastnes MH, Standal T. Molecular interactions and functions of IL-32. J Leuk Biol. 2021; 109(1):143-159.","DOI":"10.1002\/JLB.3MR0620-550R"},{"key":"42263","doi-asserted-by":"crossref","unstructured":"Sohn DH, Nguyen TT, Kim S. Structural characteristics of seven IL-32 variants. Immune Netw. 2019; 19(2):e8.","DOI":"10.4110\/in.2019.19.e8"},{"key":"42264","doi-asserted-by":"crossref","unstructured":"Han S, Yang Y. Interleukin-32: frenemy in cancer?. BMB Rep. 2019; 52(3):165.","DOI":"10.5483\/BMBRep.2019.52.3.019"},{"key":"42265","doi-asserted-by":"crossref","unstructured":"Zahoor M, Westhrin M, Aass KR. Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. Blood Adv. 2017; 1(27):2656-2666.","DOI":"10.1182\/bloodadvances.2017010801"},{"key":"42266","doi-asserted-by":"crossref","unstructured":"Kim S-H, Han S-Y, Azam T, Yoon D-Y, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFcx. Immunity. 2005; 22(1):131-142.","DOI":"10.1016\/S1074-7613(04)00380-2"},{"key":"42267","doi-asserted-by":"crossref","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020; 1(5):493-506.","DOI":"10.1038\/s43018-020-0053-3"},{"key":"42268","doi-asserted-by":"crossref","unstructured":"Kang JW, Choi SC, Cho MC. A proinflammatory cytokine interleukin-323 promotes the production of an antiinflammatory cytokine interleukin-10. Immunology. 2009; 128(1pt2):e532-e540.","DOI":"10.1111\/j.1365-2567.2008.03025.x"},{"key":"42269","doi-asserted-by":"crossref","unstructured":"Smith AJ, Toledo CM, Wietgrefe SW. The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection. J Immunol. 2011; 186(11):6576-6584.","DOI":"10.4049\/jimmunol.1100277"},{"key":"42270","doi-asserted-by":"crossref","unstructured":"Yan H, Dong M, Liu X. Multiple myeloma cell-derived IL-32\u03b3 increases the immunosuppressive function of macrophages by promoting indoleamine 2, 3-dioxygenase (IDO) expression. Cancer Lett. 2019; 446:38-48.","DOI":"10.1016\/j.canlet.2019.01.012"},{"key":"42271","doi-asserted-by":"crossref","unstructured":"Carbonnelle-Puscian A, Copie-Bergman C, Baia M. The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia. 2009; 23(5):952-960.","DOI":"10.1038\/leu.2008.380"},{"key":"42272","doi-asserted-by":"crossref","unstructured":"Nakamura K, Kassem S, Cleynen A. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018; 33(4):634-648.","DOI":"10.1016\/j.ccell.2018.02.007"},{"key":"42273","doi-asserted-by":"crossref","unstructured":"Song K, Herzog BH, Sheng M. Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res. 2013; 73(24):7254-7264.","DOI":"10.1158\/0008-5472.CAN-13-0750"},{"key":"42274","doi-asserted-by":"crossref","unstructured":"Le K, Sun J, Khawaja H. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. Blood Adv. 2021; 5(14):2863-2878.","DOI":"10.1182\/bloodadvances.2020003871"},{"key":"42275","doi-asserted-by":"crossref","unstructured":"Rodrigues JM, Nikkarinen A, Hollander P. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. Br J Haematol. 2021; 193(3):520-531.","DOI":"10.1111\/bjh.17366"},{"key":"42276","doi-asserted-by":"crossref","unstructured":"Baran-Marszak F, Boukhiar M, Harel S. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010; 95(11):1865.","DOI":"10.3324\/haematol.2009.019745"},{"key":"42277","doi-asserted-by":"crossref","unstructured":"Karvonen H, Chiron D, Niininen W. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Adv. 2017; 1(24):2257-2268.","DOI":"10.1182\/bloodadvances.2017010215"},{"key":"42278","doi-asserted-by":"crossref","unstructured":"Yang S, Li J-Y, Xu W. Role of BAFF\/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit Rev Oncol Hematol. 2014; 91(2):113-122.","DOI":"10.1016\/j.critrevonc.2014.02.004"},{"key":"42279","doi-asserted-by":"crossref","unstructured":"Zhang L, Yang J, Qian J. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012; 120(18):3783-3792.","DOI":"10.1182\/blood-2012-04-424630"},{"key":"42280","doi-asserted-by":"crossref","unstructured":"Novak AJ, Grote DM, Stenson M. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004; 104(8):2247-2253.","DOI":"10.1182\/blood-2004-02-0762"},{"key":"42281","doi-asserted-by":"crossref","unstructured":"Medina DJ, Goodell L, Glod J, G\u00e9linas C, Rabson AB, Strair RK. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor \u03baB pathways. Haematologica. 2012; 97(8):1255-1263.","DOI":"10.3324\/haematol.2011.040659"},{"key":"42282","doi-asserted-by":"crossref","unstructured":"McWilliams EM, Lucas CR, Chen T. Anti\u2013BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019; 3(3):447-460.","DOI":"10.1182\/bloodadvances.2018025684"},{"key":"42283","doi-asserted-by":"crossref","unstructured":"Tandler C, Schmidt M, Heitmann JS. Neutralization of B-cell activating factor (BAFF) by belimumab reinforces small molecule inhibitor treatment in chronic lymphocytic leukemia. Cancers. 2020; 12(10):2725.","DOI":"10.3390\/cancers12102725"},{"key":"42284","doi-asserted-by":"crossref","unstructured":"Hill HA, Qi X, Jain P. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020; 4(13):2927-2938.","DOI":"10.1182\/bloodadvances.2019001350"},{"key":"42285","doi-asserted-by":"crossref","unstructured":"Hatada EN, Do RK, Orlofsky A. NF-\u03baB1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-\u03baB2 p100 to p52 in quiescent mature B cells. J Immunol. 2003; 171(2):761-768.","DOI":"10.4049\/jimmunol.171.2.761"},{"key":"42286","doi-asserted-by":"crossref","unstructured":"Paiva C, Rowland TA, Sreekantham B. SYK inhibition thwarts the BAFF-B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017; 102(11):1890.","DOI":"10.3324\/haematol.2017.170571"},{"key":"42287","doi-asserted-by":"crossref","unstructured":"Mondrag\u00f3n L, Mhaidly R, De Donatis GM. GAPDH overexpression in the T cell lineage promotes angioimmunoblastic T cell lymphoma through an NF-\u03baB-dependent mechanism. Cancer Cell. 2019; 36(3):268-287.","DOI":"10.1016\/j.ccell.2019.07.008"},{"key":"42288","doi-asserted-by":"crossref","unstructured":"Kennedy R, Klein U. Aberrant activation of NF-\u03baB signalling in aggressive lymphoid malignancies. Cells. 2018; 7(11):189.","DOI":"10.3390\/cells7110189"},{"key":"42289","doi-asserted-by":"crossref","unstructured":"Eluard B, Nuan-Aliman S, Faumont N. The alternative RelB NF-\u03baB subunit is a novel critical player in diffuse large B-cell lymphoma. Blood. 2022; 139(3):384-398.","DOI":"10.1182\/blood.2020010039"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279800\/74245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279800\/75066","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10568\/74245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:19Z","timestamp":1794045679000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279800","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}